January 26, 2015Open Access

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

Key Points

Key points are not available for this paper at this time.

Abstract

Subjective toxicities are at high risk of under-reporting by physicians, even when prospectively collected within randomized trials. This strongly supports the incorporation of patient-reported outcomes into toxicity reporting in clinical trials.

Bookmark

View Full Paper

Cite This Study

Maïo et al. (Mon,) studied this question.

synapsesocial.com/papers/69dd6035ae7c4d5b29100e91 https://doi.org/https://doi.org/10.1200/jco.2014.57.9334

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Physicians' and patients' choices in evidence based practice2002 · 515 citations
2Statistical Methods for Rates and Proportions2003 · 18,048 citations
3Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.1996 · 431 citations
4Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S.1974 · 1,546 citations
5The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology1993 · 15,964 citations

Bookmark

View Full Paper